Coloplast (COLO B) 주식 개요
Coloplast A/S는 덴마크, 미국, 영국, 프랑스 및 전 세계에서 친밀한 헬스케어 제품 및 서비스를 개발 및 판매하는 기업입니다. 자세히 보기
COLO B Community Fair Values
Create NarrativeSee what 55 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Coloplast A/S 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | DKK 435.60 |
| 52주 최고가 | DKK 646.60 |
| 52주 최저가 | DKK 369.70 |
| 베타 | 0.55 |
| 1개월 변동 | 3.03% |
| 3개월 변동 | 5.75% |
| 1년 변동 | -27.93% |
| 3년 변동 | -45.89% |
| 5년 변동 | -60.36% |
| IPO 이후 변동 | 3,309.04% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Jul 15
COLO B: Recent P/E Reset Will Create Upside Opportunity
Analysts have lowered the fair value estimate for Coloplast to DKK 584 from DKK 868, reflecting a reset in price assumptions and P/E expectations, while recent price targets across the Street range from DKK 345 to DKK 484. Analyst Commentary Recent Street research on Coloplast shows a wide spread in views, but there are several constructive signals that point to ongoing interest in the stock at current levels.
내러티브 업데이트 • Jun 30
COLO B: Reset Expectations And New Products Will Shape Future Sentiment
The analyst price target for Coloplast has been revised from DKK 535 to DKK 345. This reflects a reset in valuation assumptions as analysts weigh recent target cuts against differing views on how the recent share selloff relates to company fundamentals and future P/E expectations.
내러티브 업데이트 • Jun 16
COLO B: Recent Pullback And New FDA Approval Will Support Future Re Rating
The analyst price target for Coloplast has been revised slightly, with the updated fair value held around DKK 462 as analysts factor in a modestly lower discount rate and only small tweaks to growth and margin assumptions following a series of recent target cuts and one new Buy initiation around DKK 482. Analyst Commentary Recent research on Coloplast highlights a split in opinion, with some analysts seeing value after the share price pullback and others focusing on execution risk and margin pressure in their updated targets.Recent updates
내러티브 업데이트 • Jul 15
COLO B: Recent P/E Reset Will Create Upside Opportunity
Analysts have lowered the fair value estimate for Coloplast to DKK 584 from DKK 868, reflecting a reset in price assumptions and P/E expectations, while recent price targets across the Street range from DKK 345 to DKK 484. Analyst Commentary Recent Street research on Coloplast shows a wide spread in views, but there are several constructive signals that point to ongoing interest in the stock at current levels.내러티브 업데이트 • Jun 30
COLO B: Reset Expectations And New Products Will Shape Future Sentiment
The analyst price target for Coloplast has been revised from DKK 535 to DKK 345. This reflects a reset in valuation assumptions as analysts weigh recent target cuts against differing views on how the recent share selloff relates to company fundamentals and future P/E expectations.내러티브 업데이트 • Jun 16
COLO B: Recent Pullback And New FDA Approval Will Support Future Re Rating
The analyst price target for Coloplast has been revised slightly, with the updated fair value held around DKK 462 as analysts factor in a modestly lower discount rate and only small tweaks to growth and margin assumptions following a series of recent target cuts and one new Buy initiation around DKK 482. Analyst Commentary Recent research on Coloplast highlights a split in opinion, with some analysts seeing value after the share price pullback and others focusing on execution risk and margin pressure in their updated targets.내러티브 업데이트 • Jun 02
COLO B: New CEO And Lower P/E Will Support Future Multiple Re Rating
The updated analyst price target for Coloplast moves from DKK 500.15 to DKK 461.90, as analysts factor in slightly firmer revenue growth assumptions, a small change in the discount rate, and a lower future P/E multiple, while recent research highlights both reduced targets and one new Buy initiation after the share selloff. Analyst Commentary Recent Street research on Coloplast reflects a mix of optimism and caution, with several firms adjusting price targets and ratings following the share selloff.분석 기사 • May 20
Some May Be Optimistic About Coloplast's (CPH:COLO B) Earnings
Shareholders appeared unconcerned with Coloplast A/S' ( CPH:COLO B ) lackluster earnings report last week. Our analysis...분석 기사 • May 15
Coloplast A/S Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next
Last week saw the newest half-year earnings release from Coloplast A/S ( CPH:COLO B ), an important milestone in the...내러티브 업데이트 • May 10
COLO B: New CEO And Reset P/E Will Support Future Multiple Re Rating
The analyst price target on Coloplast has been reduced from DKK 551.68 to DKK 500.15, as analysts incorporate a series of recent target cuts and mixed ratings while adjusting assumptions around the discount rate, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Recent Street research on Coloplast has centered on a series of target cuts and rating changes that feed directly into the revised average price target.내러티브 업데이트 • Apr 24
COLO B: New CEO Appointment Will Underpin Future Multiple Re Rating Potential
Coloplast's analyst price target has been nudged lower to about DKK 552 from roughly DKK 561, reflecting recent cuts to DKK-based targets by several banks as analysts factor in a slightly higher discount rate, a modestly adjusted future P/E assumption and only small tweaks to long term growth and margin expectations. Analyst Commentary Recent Street research around Coloplast has centered on recalibrated price targets and rating changes as analysts reassess what they are willing to pay for the company, given updated discount rates and P/E assumptions.내러티브 업데이트 • Apr 09
COLO B: New CEO Appointment Will Support Future Re Rating Potential
The updated analyst price target for Coloplast has been reduced by DKK 6.53. This change reflects a slight reset in fair value as analysts incorporate higher discount rates, marginally softer margin assumptions, and recent price target cuts, along with mixed rating changes across the Street.내러티브 업데이트 • Mar 26
COLO B: New CEO Appointment And Reset P/E Will Support Future Re Rating
Coloplast's analyst fair value target has been trimmed from DKK 579.78 to DKK 567.16, as analysts factor in slightly lower long term growth, modestly softer margin assumptions and small adjustments to future P/E expectations following a mix of recent target cuts and one upgrade. Analyst Commentary Recent research on Coloplast has been mixed, with several target cuts alongside one upgrade.내러티브 업데이트 • Mar 11
COLO B: Reset P/E And New Leadership Will Support Future Re Rating
The updated analyst price target for Coloplast has been trimmed by around DKK 9 to reflect lower Street targets. This includes cuts to DKK 504 at Deutsche Bank and reductions at RBC Capital, JPMorgan and Berenberg, as analysts factor in slightly higher discount rates, modestly softer margin assumptions and a lower future P/E multiple.내러티브 업데이트 • Feb 25
COLO B: Reset P/E And Dividend Will Support Future Re Rating
Analysts have trimmed their DKK price targets on Coloplast, reflected in a lower fair value estimate from DKK 615 to DKK 588, as they factor in slightly more cautious assumptions on growth, margins and future P/E multiples following recent target reductions from several research houses. Analyst Commentary Bullish Takeaways Bullish analysts still see room for upside from current levels, even with reduced DKK price targets.내러티브 업데이트 • Feb 10
COLO B: Reset P/E And Dividend Will Support Future Upside
Analysts have trimmed their fair value estimate for Coloplast from DKK 678.22 to DKK 615.06, reflecting recent price target cuts and updated assumptions on the discount rate, revenue growth, profit margins and future P/E multiples. Analyst Commentary Recent Street research on Coloplast has focused on recalibrating expectations rather than fundamentally changing the story.분석 기사 • Jan 25
Coloplast A/S' (CPH:COLO B) P/E Is On The Mark
Coloplast A/S' ( CPH:COLO B ) price-to-earnings (or "P/E") ratio of 33.6x might make it look like a strong sell right...내러티브 업데이트 • Jan 24
COLO B: Dividend Reliability And Premium P/E Will Support Future Upside
Analysts have lowered their Coloplast price targets by DKK 10, to a range of DKK 535 to DKK 640, reflecting slightly lower fair value assumptions, modestly softer revenue growth expectations, and a marginally reduced future P/E multiple. Analyst Commentary Recent research updates on Coloplast point to a tighter valuation range, with price targets now clustered between DKK 535 and DKK 640.내러티브 업데이트 • Jan 09
COLO B: Sustained Margins And Dividend Payouts Will Support Future Upside
Narrative update The analyst price target for Coloplast has edged up by about DKK 0.30 to reflect slightly higher fair value estimates. Recent Street research shows a mix of views, with some analysts lifting targets toward DKK 535 and others resetting them closer to DKK 640, which has led to modest adjustments to discount rate, revenue growth, profit margin, and future P/E assumptions.내러티브 업데이트 • Dec 13
COLO B: Sustained Margin Strength Will Support Upside As Dividend Payouts Increase
Analysts have nudged our Coloplast fair value estimate slightly higher to about DKK 689 per share from roughly DKK 689 previously, reflecting a modest uptick in long term multiple assumptions even as recent Street price target revisions have moved in mixed directions. Analyst Commentary Recent Street actions on Coloplast highlight a divided view on near term upside versus longer term execution and growth.분석 기사 • Dec 04
Coloplast (CPH:COLO B) Is Increasing Its Dividend To DKK18.00
Coloplast A/S ( CPH:COLO B ) has announced that it will be increasing its dividend from last year's comparable payment...내러티브 업데이트 • Nov 29
COLO B: Sustained Margin Strength Will Support Upside Amid Market Challenges
Coloplast’s analyst fair value estimate was revised slightly upward to DKK 688.67 from DKK 685.39. Analysts weighed recent price target changes along with minor adjustments to growth expectations and profit margins.분석 기사 • Nov 20
Coloplast (CPH:COLO B) Will Pay A Larger Dividend Than Last Year At DKK18.00
Coloplast A/S ( CPH:COLO B ) will increase its dividend from last year's comparable payment on the 9th of December to...내러티브 업데이트 • Nov 14
COLO B: Future Execution In Core Markets Will Drive Share Price Momentum
The analyst consensus price target for Coloplast has modestly decreased. Updated projections reflect cautious sentiment from analysts, who cite modest adjustments to growth and profitability expectations.내러티브 업데이트 • Oct 31
COLO B: Executive Team Changes And Chronic Care Strategy Will Drive Outperformance
Coloplast’s analyst price target was reduced slightly from DKK 691.83 to DKK 686.00, as analysts cite modestly lower revenue growth expectations and recent target decreases across several major firms. Analyst Commentary Recent commentary from market analysts highlights a balanced perspective on Coloplast’s outlook, with both raised and lowered price targets reflecting shifting sentiment in key performance areas.내러티브 업데이트 • Oct 17
Chronic Care Focus And Emerging Markets Will Redefine Healthcare
Coloplast's analyst price target has been reduced by nearly DKK 10 to DKK 691.83. Analysts cite mixed recent revisions in target prices, reflecting a balanced outlook amid evolving growth and margin expectations.내러티브 업데이트 • Oct 03
Chronic Care Focus And Emerging Markets Will Redefine Healthcare
Coloplast's analyst price target has been revised downward from DKK 716 to DKK 701. Analysts have adjusted their expectations in response to a series of recent target reductions following tempered growth and margin forecasts.내러티브 업데이트 • Aug 30
Chronic Care Focus And Emerging Markets Will Redefine Healthcare
Coloplast’s consensus price target was modestly reduced to DKK718.06 as analysts weighed concerns about slowing revenue growth and margin pressure against stable demand in key product portfolios and longer-term benefits from innovation and expansion. Analyst Commentary Bearish analysts cite concerns over slowing revenue growth and margin pressure, particularly in core European markets.분석 기사 • Aug 22
Coloplast A/S Just Missed EPS By 16%: Here's What Analysts Think Will Happen Next
It's been a good week for Coloplast A/S ( CPH:COLO B ) shareholders, because the company has just released its latest...
새로운 내러티브 • Nov 07
Operational Efficiencies And Innovations In Urology And Wound Care Propel Future Growth
Improved operational efficiency and strategic expansions are expected to enhance net margins and earnings over the long term.주주 수익률
| COLO B | DK Medical Equipment | DK 시장 | |
|---|---|---|---|
| 7D | -1.1% | 1.6% | 1.7% |
| 1Y | -27.9% | -17.2% | 0.3% |
수익률 대 산업: COLO B은 지난 1년 동안 -17.2%의 수익을 기록한 Danish Medical Equipment 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: COLO B은 지난 1년 동안 0.3%를 기록한 Danish 시장보다 저조한 성과를 냈습니다.
주가 변동성
| COLO B volatility | |
|---|---|
| COLO B Average Weekly Movement | 3.9% |
| Medical Equipment Industry Average Movement | 3.8% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in DK Market | 7.1% |
| 10% least volatile stocks in DK Market | 2.3% |
안정적인 주가: COLO B는 지난 3개월 동안 Danish 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: COLO B의 주간 변동성(4%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1954 | 17,083 | Gavin Wood | www.coloplast.com |
콜로플라스트 A/S는 덴마크, 미국, 영국, 프랑스 및 전 세계에서 친밀한 헬스케어 제품 및 서비스를 개발 및 판매하고 있습니다. 이 회사는 만성 관리, 실금 관리, 음성 및 호흡기 관리, 중재적 비뇨기과, 고급 상처 관리 부문을 통해 사업을 운영하고 있습니다. 다양한 유형의 장루에 개인 체형에 맞는 최적의 재량을 제공하는 센수라 미오, 센수라 장루 케어 솔루션, 브라바 브랜드의 장루 액세서리 등 장루 케어 제품을 제공합니다.
Coloplast A/S 기초 지표 요약
| COLO B 기초 통계 | |
|---|---|
| 시가총액 | DKK 98.08b |
| 순이익 (TTM) | DKK 2.11b |
| 매출 (TTM) | DKK 28.05b |
46.6x
주가수익비율(P/E)3.5x
주가매출비율(P/S)COLO B는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| COLO B 손익계산서 (TTM) | |
|---|---|
| 매출 | DKK 28.05b |
| 매출원가 | DKK 9.13b |
| 총이익 | DKK 18.92b |
| 기타 비용 | DKK 16.81b |
| 순이익 | DKK 2.11b |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
Nov 03, 2026
| 주당순이익(EPS) | 9.35 |
| 총이익률 | 67.46% |
| 순이익률 | 7.51% |
| 부채/자본 비율 | 181.5% |
COLO B의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기배당
5.3%
현재 배당 수익률246%
배당 성향기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/08/18 23:28 |
| 종가 | 2026/08/18 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/09/30 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Coloplast A/S는 42명의 분석가가 다루고 있습니다. 이 중 20명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| null null | ABG Sundal Collier |
| Hassan Al-Wakeel | Barclays |
| Robert Bate | Barclays |